NASDAQ:APLTApplied Therapeutics Stock Price, Forecast & News

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APLT stock has increased by 63.2% and is now trading at $48.29. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Applied Therapeutics.

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Applied Therapeutics.

Applied Therapeutics (NASDAQ:APLT) released its earnings results on Monday, May, 11th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.23. View Applied Therapeutics' earnings history.

6 analysts have issued twelve-month price objectives for Applied Therapeutics' shares. Their forecasts range from $43.00 to $65.00. On average, they expect Applied Therapeutics' share price to reach $55.20 in the next year. This suggests a possible upside of 14.3% from the stock's current price. View analysts' price targets for Applied Therapeutics.

News headlines about APLT stock have trended extremely positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Applied Therapeutics earned a news impact score of 5.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutApplied Therapeutics.

Applied Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 642,100 shares, an increase of 56.8% from the April 30th total of 409,500 shares. Based on an average daily volume of 196,400 shares, the short-interest ratio is presently 3.3 days. Currently, 5.1% of the company's stock are short sold. View Applied Therapeutics' Current Options Chain.

Some companies that are related to Applied Therapeutics include Nektar Therapeutics (NKTR), Zai Lab (ZLAB), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), FibroGen (FGEN), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT) and Axsome Therapeutics (AXSM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Vertex Pharmaceuticals (VRTX), Alteryx (AYX), Enterprise Products Partners (EPD), Adobe (ADBE), Medtronic (MDT), Pfizer (PFE), Verizon Communications (VZ), Advanced Micro Devices (AMD), IBM (IBM) and Netflix (NFLX).

(APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

Applied Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (6.01%), Rock Springs Capital Management LP (3.85%), Driehaus Capital Management LLC (2.69%), BlackRock Inc. (2.42%), Franklin Resources Inc. (1.55%) and Emerald Advisers LLC (1.41%). Company insiders that own Applied Therapeutics stock include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman and Stacy J Kanter. View institutional ownership trends for Applied Therapeutics.

APLT stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Federated Hermes Inc., Oppenheimer & Co. Inc., Morgan Stanley, JPMorgan Chase & Co., and UBS Group AG. View insider buying and selling activity for Applied Therapeutics.

APLT stock was purchased by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Driehaus Capital Management LLC, Franklin Resources Inc., Orbimed Advisors LLC, Emerald Advisers LLC, BlackRock Inc., Invesco Ltd., and Sphera Funds Management LTD.. Company insiders that have bought Applied Therapeutics stock in the last two years include Joel S Marcus, Real Estate Equitie Alexandria, Shoshana Shendelman, and Stacy J Kanter. View insider buying and selling activity for Applied Therapeutics.

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APLT stock can currently be purchased for approximately $48.29.

Applied Therapeutics has a market capitalization of $1.06 billion. Applied Therapeutics employs 4 workers across the globe.

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]